

Pamela J Goodwin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8443872/pamela-j-goodwin-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175
papers

18,943
citations

63
h-index

137
g-index

198
ext. papers

21,482
ext. citations

7.3
avg, IF

6.55
L-index

#	Paper	IF	Citations
175	A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination.. <i>Clinical and Translational Immunology</i> , 2022 , 11, e1380	6.8	3
174	Abstract GS1-08: CCTGMA.32, a phase III randomized double-blind placebo controlled adjuvant trial of metformin (MET) vs placebo (PLAC) in early breast cancer (BC): Results of the primary efficacy analysis (clinical trials.gov NCT01101438). <i>Cancer Research</i> , 2022 , 82, GS1-08-GS1-08	10.1	1
173	The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention.. <i>Obesity</i> , 2022 , 30, 28-38	8	0
172	Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 1963	27.4	5
171	Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial. <i>Npj Breast Cancer</i> , 2021 , 7, 74	7.8	7
170	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. <i>Npj Breast Cancer</i> , 2021 , 7, 77	7.8	7
169	The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 192-198	9.7	10
168	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 1465-1475	9.7	10
167	Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis. <i>Npj Breast Cancer</i> , 2021 , 7, 97	7.8	4
166	Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab066	4.6	1
165	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. <i>Npj Breast Cancer</i> , 2020 , 6, 22	7.8	4
164	The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 6	7.8	9
163	Prognostic associations of plasma hepcidin in women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 927-935	4.4	1
162	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. <i>Breast</i> , 2019 , 48, 17-23	3.6	38
161	Can We Find the Positive in Negative Clinical Trials?. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 637-638	9.7	2
160	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz049	4.6	4
159	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz050	4.6	6

158	Sexual health in long-term breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 159-166	4.4	14
157	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky028	4.6	6
156	Weight management and physical activity throughout the cancer care continuum. <i>Ca-A Cancer Journal for Clinicians</i> , 2018 , 68, 64-89	220.7	75
155	Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 451-460	4.4	8
154	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 371-378	4.4	8
153	De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. <i>Annals of Oncology</i> , 2017 , 28, 1700-1712	10.3	586
152	Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. <i>Npj Breast Cancer</i> , 2017 , 3, 37	7.8	54
151	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017 , 377, 1836-1846	59.2	610
150	Obesity and breast cancer - what's new?. <i>Expert Review of Endocrinology and Metabolism</i> , 2017 , 12, 35-43	4.1	1
149	Obesity and Cancer: Insights for Clinicians. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4197-4202	2.2	25
148	Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4203-4216	2.2	168
147	Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4249-4255	2.2	55
146	Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy. <i>Cell Metabolism</i> , 2016 , 23, 567-8	24.6	79
145	Breast Cancer Survivorship: Where Are We Today?. <i>Advances in Experimental Medicine and Biology</i> , 2015 , 862, 1-8	3.6	53
144	Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes. <i>Advances in Experimental Medicine and Biology</i> , 2015 , 862, 155-75	3.6	18
143	Host Factors and Risk of Breast Cancer Recurrence: Genetic, Epigenetic and Biologic Factors and Breast Cancer Outcomes. <i>Advances in Experimental Medicine and Biology</i> , 2015 , 862, 143-53	3.6	10
142	Modifiable Lifestyle Factors and Breast Cancer Outcomes: Current Controversies and Research Recommendations. <i>Advances in Experimental Medicine and Biology</i> , 2015 , 862, 177-92	3.6	20
141	Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study. <i>Breast Cancer Research</i> , 2015 , 17, 32	8.3	76

140	Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015 , 26, 1533-46	10.3	1122
139	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 605-11	4.4	17
138	Obesity, insulin resistance and breast cancer outcomes. <i>Breast</i> , 2015 , 24 Suppl 2, S56-9	3.6	19
137	Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3961-7	2.2	44
136	Impact of the obesity epidemic on cancer. <i>Annual Review of Medicine</i> , 2015 , 66, 281-96	17.4	128
135	Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	88
134	Progesterone and Synthetic Progestin Controversies--Reply. <i>JAMA Oncology</i> , 2015 , 1, 987-8	13.4	
133	Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 149-55	4.4	63
132	Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2231-9	2.2	114
131	Past, present, and future challenges in breast cancer treatment. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1979-86	2.2	142
130	Hype versus hope: metformin and vitamin D as anticancer agents. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014 , e69-74	7.1	2
129	Pain in patients with cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1637-9	2.2	18
128	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013 , 24, 2206-23	10.3	2048
127	Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 331-9	4.4	60
126	Post-surgical highly sensitive C-reactive protein and prognosis in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 485-93	4.4	13
125	Obesity and endocrine therapy: host factors and breast cancer outcome. <i>Breast</i> , 2013 , 22 Suppl 2, S44-7	3.6	33
124	Association between metformin therapy and mortality after breast cancer: a population-based study. <i>Diabetes Care</i> , 2013 , 36, 3018-26	14.6	82
123	Quality of life in long-term breast cancer survivors. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3540-8	2.2	85

122	Reply to C.M. Booth et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3300		2.2
121	A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 th following adjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 143-51	4.4	6
120	Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 821-30	4.4	188
119	Obesity and Insulin Resistance in Breast Cancer: Are Clinical Trials Needed?. <i>Breast Diseases</i> , 2012 , 23, 310-313		1
118	Metformin in cancer: translational challenges. <i>Journal of Molecular Endocrinology</i> , 2012 , 48, R31-43	4.5	243
117	Second malignant neoplasms: assessment and strategies for risk reduction. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3734-45	2.2	190
116	The role of obesity in cancer survival and recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1244-59	4	206
115	25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 1077-88	4.4	44
114	Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 769-81	4.4	140
113	Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 759-67	4.4	15
112	Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations. <i>Journal of Clinical Oncology</i> , 2012 , 30, 164-71	2.2	152
111	Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 19-26	2.2	116
110	Intake of phytoestrogen foods and supplements among women recently diagnosed with breast cancer in Ontario, Canada. <i>Nutrition and Cancer</i> , 2012 , 64, 695-703	2.8	28
109	Journal of Clinical Oncology update on progress in cancer survivorship care and research. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3655-6	2.2	28
108	Breast cancer survivors: taking charge of lifestyle choices after treatment. <i>European Journal of Oncology Nursing</i> , 2011 , 15, 250-3	2.8	9
107	Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. <i>Breast</i> , 2011 , 20 Suppl 3, S31-5	3.6	53
106	Understanding the benefit of metformin use in cancer treatment. <i>BMC Medicine</i> , 2011 , 9, 33	11.4	256
105	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 215-20	4.4	154

104	Breast cancer chemoprevention gets personal. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2296-8	2.2	2
103	Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). <i>Journal of the National Cancer Institute</i> , 2011 , 103, 178-231	9.7	77
102	Insulin Resistance: Clinical Implications for Cancer Treatment and Prevention. <i>Energy Balance and Cancer</i> , 2011 , 269-291	0.2	
101	Host factors and cancer outcome. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4019-21	2.2	18
100	Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5147-52	2.2	82
99	Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. <i>Cancer Prevention Research</i> , 2010 , 3, 1451-61	3.2	659
98	Metabolic Syndrome, Insulin Resistance, and Inflammation in Breast Cancer: Impact on Prognosis and Adjuvant Interventions. <i>Current Breast Cancer Reports</i> , 2010 , 2, 182-189	0.8	2
97	Prognosis of BRCA-associated breast cancer: a summary of evidence. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 13-24	4.4	96
96	Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 647-59	4.4	32
95	Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 531-42	4.4	43
94	Commentary on: "Effect of obesity on survival in women with breast cancer: systematic review and meta-analysis" (Melinda Protani, Michael Coory, Jennifer H. Martin). <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 637-40	4.4	13
93	Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 630-43	9.7	88
92	Reply to R.M. Memmott et al. <i>Journal of Clinical Oncology</i> , 2009 , 27, e227-e227	2.2	
91	Insulin-insulin-like growth factor axis and colon cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 165-7	2.2	46
90	Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3757-63	2.2	263
89	Reply to A. Vazquez-Martin et al. <i>Journal of Clinical Oncology</i> , 2009 , 27, e210-e210	2.2	1
88	Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 1792-7	4	25
87	Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 387-9	4.4	35

86	High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 517-25	4.4	71
85	Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , 2009 , 117, 167-76	4.4	18
84	Metformin in breast cancer: time for action. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3271-3	2.2	162
83	Tibolone: the risk is too high. <i>Lancet Oncology</i> , 2009 , 10, 103-4	21.7	3
82	Insulin-lowering effects of metformin in women with early breast cancer. <i>Clinical Breast Cancer</i> , 2008 , 8, 501-5	3	191
81	Identification of cancer care and protocol characteristics associated with recruitment in breast cancer clinical trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4458-65	2.2	33
80	Host-related factors in breast cancer: an underappreciated piece of the puzzle?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3299-300	2.2	13
79	The impact of diabetes on survival following breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 109, 389-95	4.4	137
78	Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. <i>BMC Cancer</i> , 2007 , 7, 99	4.8	19
77	Responsiveness to change [corrected] due to supportive-expressive group therapy, improvement in mood and disease progression in women with metastatic breast cancer. <i>Quality of Life Research</i> , 2007 , 16, 1007-17	3.7	8
76	Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2007 , 105, 69-80	4.4	43
75	Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007 , 106, 39-47	4.4	83
74	Health-related quality of life measurement in symptom management trials. <i>Journal of the National Cancer Institute Monographs</i> , 2007 , 47-52	4.8	7
73	Second consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 215-25.3	5.3	83
72	The history and contemporary challenges of the US Food and Drug Administration. <i>Clinical Therapeutics</i> , 2007 , 29, 1-16	3.5	49
71	Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. <i>Clinical Therapeutics</i> , 2007 , 29, 230-41	3.5	85
70	Three methods for minimally important difference: no relationship was found with the net proportion of patients improving. <i>Journal of Clinical Epidemiology</i> , 2007 , 60, 448-55	5.7	65
69	Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. <i>New England Journal of Medicine</i> , 2007 , 357, 1555; author reply 1556	59.2	78

68	Medical, Psychosocial, and Health-Related Quality of Life Issues in Breast Cancer Survivors 2007 , 122-144		8
67	Reliability and validity of the body image after breast cancer questionnaire. <i>Breast Journal</i> , 2006 , 12, 221-32	1.2	81
66	Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. <i>Breast Cancer Research and Treatment</i> , 2006 , 98, 303-9	4.4	59
65	Diabetes mellitus and breast cancer: a retrospective population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2006 , 98, 349-56	4.4	78
64	Economic analysis of psychosocial group therapy in women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 183-90	4.4	28
63	Medical, Psychosocial, and Health-Related Quality of Life Issues in Breast Cancer Survivors 2006 , 1846-1868		
62	Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6037-42	2.2	69
61	Support groups in advanced breast cancer. <i>Cancer</i> , 2005 , 104, 2596-601	6.4	23
60	Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2005 , 94, 135-44	4.4	50
59	Options for preservation of fertility in women. <i>New England Journal of Medicine</i> , 2005 , 353, 1418-20; author reply 1418-20	59.2	8
58	Energy Balance and Cancer Prognosis, Breast Cancer. <i>Nutrition and Disease Prevention</i> , 2005 , 405-435		3
57	Quality of life in breast cancer: what have we learned and where do we go from here? 2004 , 93-125		3
56	Support groups in breast cancer: when a negative result is positive. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4244-6	2.2	14
55	Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4184-92	2.2	79
54	Diet and breast cancer: evidence that extremes in diet are associated with poor survival. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2500-7	2.2	73
53	Reversible ovarian ablation or chemotherapy: are we ready for quality of life to guide adjuvant treatment decisions in breast cancer?. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4474-5	2.2	9
52	Psychosocial Support for Women with Advanced Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 103-110	4.4	4
51	Consensus on Medical Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 1-7	4.4	31

50	Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 263-81	9.7	183
49	Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1944-51	2.2	115
48	Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1344-52	2.2	47
47	Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 42-51	2.2	705
46	HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. <i>Cancer</i> , 2002 , 95, 2068-75	6.4	49
45	Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. <i>Breast Cancer Research and Treatment</i> , 2002 , 74, 65-76	4.4	93
44	Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 42-51	2.2	329
43	Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1344-1352	2.2	39
42	The effect of group psychosocial support on survival in metastatic breast cancer. <i>New England Journal of Medicine</i> , 2001 , 345, 1719-26	59.2	702
41	Weight gain in early-stage breast cancer: where do we go from here?. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2367-9	2.2	23
40	Multilayer bandaging plus compression hosiery was better than hosiery alone for unilateral lymphedema of a limb. <i>ACP Journal Club</i> , 2001 , 134, 56		
39	Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. <i>Clinical Genetics</i> , 2000 , 57, 376-83	4	39
38	Management of familial breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2000 , 62, 19-33	4.4	10
37	Economic issues in lung cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2000 , 21, 375-84	3.9	5
36	Lessons learned from enrollment in the BEST study--a multicenter, randomized trial of group psychosocial support in metastatic breast cancer. <i>Journal of Clinical Epidemiology</i> , 2000 , 53, 47-55	5.7	38
35	Women with breast cancer were more satisfied with general practitioner care than with outpatient clinic care. <i>ACP Journal Club</i> , 2000 , 132, 106		1
34	Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. <i>Journal of Clinical Oncology</i> , 1999 , 17, 120-9	2.2	245
33	Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3653-63	2.2	82

32	Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 469-73	9.7	85
31	Factor analysis of the psychosocial items of the EORTC QLQ-C30 in metastatic breast cancer patients participating in a psychosocial intervention study. <i>Quality of Life Research</i> , 1999 , 8, 311-7	3.7	26
30	The Fox guarding the clinical trial: internal vs. external validity in randomized studies. <i>Psycho-Oncology</i> , 1999 , 8, 275	3.9	5
29	Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1241-7	9.7	326
28	Convergent discriminative, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core Quality of Life Questionnaire. <i>Journal of Clinical Epidemiology</i> , 1999 , 52, 653-66	5.7	55
27	The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. <i>American Journal of Human Genetics</i> , 1999 , 65, 1776-9	11	15
26	Risk of menopause during the first year after breast cancer diagnosis. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2365-70	2.2	453
25	Insulin and related factors in premenopausal breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 1998 , 47, 111-20	4.4	246
24	Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. <i>Breast Cancer Research and Treatment</i> , 1998 , 48, 53-64	4.4	96
23	Elevated high-density lipoprotein cholesterol and dietary fat intake in women with cyclic mastopathy. <i>American Journal of Obstetrics and Gynecology</i> , 1998 , 179, 430-7	6.4	15
22	Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients. <i>European Journal of Cancer</i> , 1998 , 34, 510-7	7.5	105
21	Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. European Organization for Research and Treatment of Cancer. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 127-45	5.7	67
20	The rationale and foundations of group psychotherapy for women with metastatic breast cancer. <i>International Journal of Group Psychotherapy</i> , 1998 , 48, 245-73	0.5	56
19	Monounsaturated fat was associated with a decreased risk for breast cancer, and polyunsaturated fat showed an increased risk. <i>ACP Journal Club</i> , 1998 , 129, 19		
18	Elevated levels of plasma triglycerides are associated with histologically defined premenopausal breast cancer risk. <i>Nutrition and Cancer</i> , 1997 , 27, 284-92	2.8	42
17	Breast health and associated premenstrual symptoms in women with severe cyclic mastopathy. <i>American Journal of Obstetrics and Gynecology</i> , 1997 , 176, 998-1005	6.4	23
16	Attitudes of Canadian oncology practitioners toward psychosocial interventions in clinical and research settings in women with breast cancer. <i>Psycho-Oncology</i> , 1997 , 6, 178-89	3.9	19
15	Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer 1997 , 6, 178		3

14	Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Breast-Expressive Supportive Therapy study. <i>Cancer Treatment Reviews</i> , 1996 , 22 Suppl A, 91-6	14.4	38
13	Cyclical mastopathy and premenopausal breast cancer risk. Results of a case-control study. <i>Breast Cancer Research and Treatment</i> , 1995 , 33, 63-73	4.4	28
12	Mammography reduces long-term mortality for women aged 50 to 74 years. <i>ACP Journal Club</i> , 1995 , 123, 34		
11	A benefits package for breast cancer includes selective screening, choice of surgery, adjuvant therapy, and no routine follow-up. <i>ACP Journal Club</i> , 1995 , 123, 35		
10	Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. <i>Lancet, The</i> , 1994 , 343, 886-9	4.0	437
9	QOL measurement in lung cancer. <i>Pharmacoeconomics</i> , 1993 , 3, 422-3	4.4	
8	Economic factors in cancer palliation--methodologic considerations. <i>Cancer Treatment Reviews</i> , 1993 , 19 Suppl A, 59-65	14.4	11
7	The restaging of responding patients with limited small cell lung cancer. Is it really useful?. <i>Chest</i> , 1993 , 103, 1010-6	5.3	4
6	Alcohol and breast cancer risk--putting the current controversy into perspective. <i>Breast Cancer Research and Treatment</i> , 1991 , 19, 221-31	4.4	13
5	Body size and breast cancer prognosis: a critical review of the evidence. <i>Breast Cancer Research and Treatment</i> , 1990 , 16, 205-14	4.4	135
4	The costs of cancer therapy. <i>European Journal of Cancer & Clinical Oncology</i> , 1990 , 26, 223-5		7
3	Cyclical mastopathy: a critical review of therapy. <i>British Journal of Surgery</i> , 1988 , 75, 837-44	5.3	14
2	Weight gain in women with localized breast cancer--a descriptive study. <i>Breast Cancer Research and Treatment</i> , 1988 , 11, 59-66	4.4	82
1	Mammographic parenchymal pattern and breast cancer risk: a critical appraisal of the evidence. <i>American Journal of Epidemiology</i> , 1988 , 127, 1097-108	3.8	56